Medicamen Biotec

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE646B01010
NSEID: MEDICAMEQ
BSEID: 531146
View on NSE | View on BSE

INR

274.80

-0.4 (-0.15%)

BSENSE

Mar 13

BSE+NSE Vol: 18.9 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Medico Remedies

Haleos Labs Limi

Amanta Healthcar

Jenburkt Pharma

Albert David

Medicamen Biotec

Valiant Laborato

Zim Laboratories

Influx Health.

Solara Active PP

Infinium Pharma

Why is Medicamen Biotech Ltd ?

Poor long term growth as Operating profit has grown by an annual rate -15.30% of over the last 5 years

PBT LESS OI(Q) At Rs 1.58 cr has Fallen at -57.75%
ROCE(HY) Lowest at 4.69%
DEBTORS TURNOVER RATIO(HY) Lowest at 2.13 times

Below par performance in long term as well as near term

Along with generating -35.82% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Medicamen Biotec for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Medicamen Biotec

-36.39%

-0.87

40.93%

Sensex

1.79%

0.16

12.13%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.71%

EBIT Growth (5y)

-15.30%

EBIT to Interest (avg)

6.17

Debt to EBITDA (avg)

1.40

Net Debt to Equity (avg)

-0.02

Sales to Capital Employed (avg)

0.67

Tax Ratio

23.51%

Dividend Payout Ratio

11.63%

Pledged Shares

Institutional Holding

0.51%

ROCE (avg)

7.68%

ROE (avg)

6.41%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.35

EV to EBIT

55.74

EV to EBITDA

29.16

EV to Capital Employed

1.35

EV to Sales

2.19

PEG Ratio

8.05

Dividend Yield

0.37%

ROCE (Latest)

3.14%

ROE (Latest)

3.88%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 43.68 cr

-7What is not working for the Company

PBT LESS OI(Q)

At Rs 1.58 cr has Fallen at -57.75%

ROCE(HY)

Lowest at 4.69%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.13 times

Loading Valuation Snapshot...

Here's what is working for Medicamen Biotec

Cash and Cash Equivalents - Half Yearly

Highest at Rs 43.68 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Medicamen Biotec

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 1.58 cr has Fallen at -57.75%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Debtors Turnover Ratio- Half Yearly

Lowest at 2.13 times

in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio